BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33278845)

  • 1. A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Hotinski AK; Best OG; Thurgood LA; Lower KM; Kuss BJ
    Br J Haematol; 2021 Feb; 192(3):e77-e81. PubMed ID: 33278845
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Pepper AGS; Zucchetto A; Norris K; Tissino E; Polesel J; Soe Z; Allsup D; Hockaday A; Ow PL; Hillmen P; Rawstron A; Catovsky D; Bulian P; Bomben R; Baird DM; Fegan CD; Gattei V; Pepper C
    Leukemia; 2022 Jan; 36(1):271-274. PubMed ID: 34148055
    [No Abstract]   [Full Text] [Related]  

  • 5. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
    Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
    Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi-clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status.
    Sheikholeslami MR; Ma W; Uyeji J; Tornyos K; Cone L; Mamus S; Albitar M
    Br J Haematol; 2007 Nov; 139(3):507-9. PubMed ID: 17868045
    [No Abstract]   [Full Text] [Related]  

  • 7. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
    Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
    Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
    Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
    Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia.
    Sellmann L; Gesk S; Walter C; Ritgen M; Harder L; Martín-Subero JI; Schroers R; Siemer D; Nückel H; Dyer MJ; Dührsen U; Siebert R; Dürig J; Küppers R
    Br J Haematol; 2007 Jul; 138(2):217-20. PubMed ID: 17593029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
    Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Strati P; Parikh SA; Chaffee KG; Achenbach SJ; Slager SL; Call TG; Ding W; Jelinek DF; Hanson CA; Kay NE; Shanafelt TD
    Br J Haematol; 2017 Jul; 178(1):99-105. PubMed ID: 28386906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.
    Osman A; Gocke CD; Gladstone DE
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):97-99. PubMed ID: 28041846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
    Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
    Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemia.
    Bühler A; Zenz T; Stilgenbauer S
    Clin Cancer Res; 2010 Jan; 16(2):373-5. PubMed ID: 20068107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
    Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia.
    Huet S; Bouvard A; Ferrant E; Mosnier I; Chabane K; Salles G; Michallet AS; Hayette S; Sujobert P
    Leukemia; 2020 Aug; 34(8):2257-2259. PubMed ID: 31996767
    [No Abstract]   [Full Text] [Related]  

  • 19. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
    Langerak AW; Davi F; Stamatopoulos K
    Br J Haematol; 2020 Jun; 189(5):809-810. PubMed ID: 32002980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.